sur SWK Holdings Corp.
SWK Holdings Updates Portfolio and Announces Q3 Earnings Date
SWK Holdings Corporation, specializing in life science finance, has announced the timing for its third-quarter earnings release and conference call. The financials will be published after market close on November 14, 2024, followed by a conference call on November 15, 2024.
In portfolio updates, SWK expanded Eton Pharmaceuticals' credit facility to $30 million, supporting Eton’s acquisition of Increlex. Epica International repaid an $8.3 million loan, with SWK retaining equity interest.
Notable performance updates include AOTI, Inc. reporting a 26.4% revenue increase and Biotricity, Inc. projecting profitability by the fiscal fourth quarter. Meanwhile, Elutia Inc. reported significant sales growth, and Journey Medical Corporation saw a 14% revenue increase.
Eton Pharmaceuticals achieved 40% year-over-year revenue growth. MolecuLight closed a $11.7 million financing round, and Shield Therapeutics reported a 320% revenue increase.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SWK Holdings Corp.